ストックスクリーナーアプリを入手
408.17
1.98%
-8.0827
前日終値:
$416.25
開ける：
$415.61
24時間の取引高:
407.46K
Relative Volume:
0.25
時価総額：
$104.55B
収益：
$11.74B
当期純損益:
$3.68B
株価収益率:
28.77
EPS:
14.1888
ネットキャッシュフロー:
$3.50B
1週間 パフォーマンス:
-4.13%
1か月 パフォーマンス:
-0.56%
6か月 パフォーマンス:
-6.17%
1年 パフォーマンス:
-18.80%
1日の値動き範囲:
$407.64
$416.27
1週間の範囲:
$403.16
$430.71
52週間の値動き範囲:
$362.50
$519.88
Vertex Pharmaceuticals Inc Stock (VRTX) Company Profile
名前
Vertex Pharmaceuticals Inc
セクター
電話
(617) 341-6393
住所
50 NORTHERN AVENUE, BOSTON, MA
VRTX を他の銘柄と比較する
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
VRTX
Vertex Pharmaceuticals Inc
|
407.77 | 105.61B | 11.74B | 3.68B | 3.50B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
645.06 | 67.99B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
432.00 | 58.19B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ARGX
Argen X Se Adr
|
843.11 | 52.40B | 3.06B | 1.28B | 447.35M | 19.67 |
|
INSM
Insmed Inc
|
183.22 | 39.60B | 447.02M | -1.18B | -906.14M | -6.1812 |
Vertex Pharmaceuticals Inc Stock (VRTX) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2025-09-25 | アップグレード | Leerink Partners | Market Perform → Outperform |
| 2025-09-03 | 開始されました | Raymond James | Mkt Perform |
| 2025-08-06 | アップグレード | Wells Fargo | Equal Weight → Overweight |
| 2025-05-07 | ダウングレード | Wolfe Research | Outperform → Peer Perform |
| 2025-05-06 | ダウングレード | Leerink Partners | Outperform → Market Perform |
| 2025-04-22 | 再開されました | Cantor Fitzgerald | Overweight |
| 2025-02-12 | アップグレード | Canaccord Genuity | Sell → Hold |
| 2025-02-11 | アップグレード | Canaccord Genuity | Sell → Hold |
| 2025-01-30 | ダウングレード | Wells Fargo | Overweight → Equal Weight |
| 2024-12-20 | 繰り返されました | H.C. Wainwright | Buy |
| 2024-12-19 | ダウングレード | Oppenheimer | Outperform → Perform |
| 2024-12-09 | アップグレード | Jefferies | Hold → Buy |
| 2024-11-14 | 開始されました | Citigroup | Buy |
| 2024-10-16 | 開始されました | Scotiabank | Sector Perform |
| 2024-10-10 | 再開されました | Raymond James | Mkt Perform |
| 2024-08-05 | ダウングレード | Barclays | Overweight → Equal Weight |
| 2024-06-27 | 開始されました | Redburn Atlantic | Buy |
| 2024-04-11 | アップグレード | Evercore ISI | In-line → Outperform |
| 2024-02-15 | 開始されました | Wolfe Research | Outperform |
| 2024-02-06 | ダウングレード | Evercore ISI | Outperform → In-line |
| 2024-02-02 | ダウングレード | Bernstein | Outperform → Mkt Perform |
| 2024-01-31 | ダウングレード | Maxim Group | Buy → Hold |
| 2024-01-31 | ダウングレード | Robert W. Baird | Neutral → Underperform |
| 2024-01-24 | ダウングレード | Canaccord Genuity | Hold → Sell |
| 2023-12-14 | 繰り返されました | RBC Capital Mkts | Sector Perform |
| 2023-05-30 | 開始されました | William Blair | Outperform |
| 2023-05-04 | 再開されました | Piper Sandler | Overweight |
| 2023-03-21 | 開始されました | Bernstein | Outperform |
| 2023-01-18 | 開始されました | Canaccord Genuity | Hold |
| 2023-01-17 | アップグレード | SVB Leerink | Mkt Perform → Outperform |
| 2022-12-19 | ダウングレード | Jefferies | Buy → Hold |
| 2022-07-13 | 開始されました | Cantor Fitzgerald | Overweight |
| 2022-06-01 | アップグレード | Maxim Group | Hold → Buy |
| 2022-05-23 | 開始されました | SVB Leerink | Mkt Perform |
| 2022-05-06 | ダウングレード | Robert W. Baird | Outperform → Neutral |
| 2022-05-03 | アップグレード | Morgan Stanley | Underweight → Equal-Weight |
| 2022-02-03 | ダウングレード | RBC Capital Mkts | Outperform → Sector Perform |
| 2022-01-27 | 繰り返されました | JP Morgan | Overweight |
| 2022-01-27 | 繰り返されました | Morgan Stanley | Underweight |
| 2022-01-27 | 繰り返されました | RBC Capital Mkts | Outperform |
| 2022-01-27 | 繰り返されました | Stifel | Hold |
| 2022-01-27 | 繰り返されました | Wolfe Research | Outperform |
| 2022-01-20 | アップグレード | BMO Capital Markets | Market Perform → Outperform |
| 2021-12-09 | 開始されました | Wells Fargo | Overweight |
| 2021-11-19 | 開始されました | BMO Capital Markets | Market Perform |
| 2021-11-19 | ダウングレード | Piper Sandler | Overweight → Neutral |
| 2021-09-09 | ダウングレード | Stifel | Buy → Hold |
| 2021-09-07 | ダウングレード | Morgan Stanley | Equal-Weight → Underweight |
| 2021-07-20 | ダウングレード | SVB Leerink | Mkt Perform → Underperform |
| 2021-07-19 | 再開されました | Wolfe Research | Outperform |
| 2021-07-01 | 開始されました | Raymond James | Mkt Perform |
| 2021-06-11 | ダウングレード | Daiwa Securities | Outperform → Neutral |
| 2021-02-23 | アップグレード | Robert W. Baird | Neutral → Outperform |
| 2021-02-02 | 繰り返されました | H.C. Wainwright | Buy |
| 2020-12-30 | 開始されました | Daiwa Securities | Outperform |
| 2020-11-30 | アップグレード | RBC Capital Mkts | Sector Perform → Outperform |
| 2020-11-20 | 開始されました | Bernstein | Outperform |
| 2020-10-28 | 開始されました | UBS | Buy |
| 2020-07-31 | 繰り返されました | H.C. Wainwright | Buy |
| 2020-07-08 | ダウングレード | Morgan Stanley | Overweight → Equal-Weight |
| 2020-04-30 | 繰り返されました | H.C. Wainwright | Buy |
| 2020-04-28 | ダウングレード | RBC Capital Mkts | Outperform → Sector Perform |
| 2020-03-04 | 開始されました | Barclays | Overweight |
| 2020-01-31 | ダウングレード | Robert W. Baird | Outperform → Neutral |
| 2019-11-19 | アップグレード | Guggenheim | Neutral → Buy |
| 2019-11-12 | 開始されました | SunTrust | Buy |
| 2019-10-17 | 再開されました | BofA/Merrill | Buy |
| 2019-09-03 | アップグレード | Goldman | Neutral → Buy |
| 2019-08-01 | ダウングレード | Needham | Buy → Hold |
| 2019-05-23 | 再開されました | Citigroup | Buy |
| 2019-05-21 | 開始されました | Credit Suisse | Outperform |
| 2019-04-12 | 開始されました | Evercore ISI | In-line |
| 2019-03-26 | アップグレード | William Blair | Mkt Perform → Outperform |
| 2019-03-19 | ダウングレード | SVB Leerink | Outperform → Mkt Perform |
| 2019-02-06 | ダウングレード | Maxim Group | Buy → Hold |
すべてを表示
Vertex Pharmaceuticals Inc (VRTX) 最新ニュース
UBS Adjusts Price Target on Vertex Pharmaceuticals to $546 From $553, Maintains Buy Rating - MarketScreener
Vertex Pharmaceuticals Incorporated (VRTX) is Attracting Investor Attention: Here is What You Should Know - Yahoo! Finance Canada
Visual analytics tools that track Vertex Pharmaceuticals Incorporated performanceShort Setup & Capital Efficient Trade Techniques - newser.com
Vertex Pharmaceuticals Incorporated’s volatility index tracking explainedJuly 2025 Reactions & AI Powered Market Entry Ideas - newser.com
Top Biotech Stocks To Follow TodayNovember 3rd - MarketBeat
Is Vertex Pharmaceuticals Incorporated stock a smart buy before Fed meeting2025 Volatility Report & Proven Capital Preservation Tips - newser.com
Exit strategy if you’re trapped in Vertex Pharmaceuticals IncorporatedJuly 2025 Volume & Fast Moving Market Watchlists - newser.com
Nasdaq, Vertex CEOs talk biotech public markets, AI at Boston event - The Business Journals
Agree To Buy Vertex Pharmaceuticals At $290, Earn 6.5% Using Options - Nasdaq
Why Vertex Pharmaceuticals Incorporated (VX1) stock signals breakout potential2025 Biggest Moves & Community Trade Idea Sharing Platform - newser.com
Will Vertex Pharmaceuticals Incorporated benefit from macro trends2025 Trading Recap & Real-Time Chart Pattern Alerts - newser.com
How big funds are accumulating Vertex Pharmaceuticals Incorporated (VX1) stockWeekly Investment Report & Growth Oriented Trading Recommendations - newser.com
Will Vertex Pharmaceuticals Incorporated bounce back from current supportTake Profit & Verified Swing Trading Watchlist - newser.com
Will Vertex Pharmaceuticals Incorporated stock maintain dividend yieldJuly 2025 Momentum & AI Enhanced Market Trend Forecasts - fcp.pa.gov.br
Promising Biotech Stocks To Watch NowNovember 4th - MarketBeat
Royal Bank Of Canada Issues Pessimistic Forecast for Vertex Pharmaceuticals (NASDAQ:VRTX) Stock Price - MarketBeat
VRTX's New Drugs Performance Mixed in Q3: Can Their Sales Improve? - TradingView
Long term hold vs stop loss in Vertex Pharmaceuticals Incorporated2025 Trade Ideas & AI Based Buy/Sell Signal Reports - newser.com
Barclays Sticks to Their Hold Rating for Vertex Pharmaceuticals (VRTX) - The Globe and Mail
Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) Q3 2025 Earnings Call Transcript - Insider Monkey
Milestone Asset Management LLC Invests $1.13 Million in Vertex Pharmaceuticals Incorporated $VRTX - MarketBeat
Bryce Point Capital LLC Purchases 710 Shares of Vertex Pharmaceuticals Incorporated $VRTX - MarketBeat
Is Vertex Pharmaceuticals Incorporated stock supported by innovation pipelineWeekly Trend Summary & Community Trade Idea Sharing Platform - newser.com
Huntington National Bank Has $14.88 Million Stake in Vertex Pharmaceuticals Incorporated $VRTX - MarketBeat
Vertex Pharma's Painkiller Collapse Sends Shockwaves—But One Drug Could Save It All! - Smartkarma
Vertex Pharmaceuticals (VRTX) Returns to Profitability, Challenging Bearish Narratives on Earnings Quality - Yahoo Finance
Vertex Pharmaceuticals Q3 2025 Earnings Call Highlights - TipRanks
Barclays Maintains Vertex Pharmaceuticals (VRTX) Equal-Weight Recommendation - Nasdaq
Vertex Pharmaceuticals: JOURNAVX Prescription Demand And Povetacicept Developments Warrant "Strong Buy" - Seeking Alpha
VRTX Q3 Deep Dive: New Product Launches and Pipeline Progress Shape Outlook - The Globe and Mail
Vertex Pharmaceuticals (NASDAQ:VRTX) Posts Earnings Results, Misses Expectations By $0.34 EPS - MarketBeat
Why Vertex Skidded Despite Its Beat-And-Raise Quarter - Investor's Business Daily
Committee stocks on the move: Uber and Vertex Pharma - MSN
RBC Capital Maintains Vertex Pharmaceuticals (VRTX) Rating, Lowe - GuruFocus
Vertex Q3 Earnings Beat, Stock Down as Casgevy Sales Disappoint - sharewise.com
Vertex’s new pain, blood disorder drugs miss Wall Street expectations - BioPharma Dive
Vertex shares slide on reliance on old product - The Pharma Letter
Vertex Pharmaceuticals: Promising IgAN Market Position with Povetacicept’s Superior Efficacy and Patient-Friendly Administration - TipRanks
Analyst Barclays Maintains 'Equal-Weight' for VRTX, Raises PT to $414 | VRTX Stock News - GuruFocus
Vertex’s New Products Dim as Analysts Eye Kidney Portfolio - BioSpace
Bernstein Adjusts Price Target on Vertex Pharmaceuticals to $466 From $471, Maintains Market Perform Rating - MarketScreener
Barclays Adjusts Price Target on Vertex Pharmaceuticals to $414 From $408, Maintains Equalweight Rating - MarketScreener
Stifel Adjusts Price Target on Vertex Pharmaceuticals to $445 From $455, Maintains Hold Rating - MarketScreener
VRTX: Stifel Lowers Price Target While Maintaining Hold Rating | - GuruFocus
Vertex touts Journavx launch metrics after novel pain med came up just short of expectations in Q3 - Fierce Pharma
RBC Lowers Price Target on Vertex Pharmaceuticals to $415 From $423, Keeps Sector Perform Rating - MarketScreener
Is Vertex Pharmaceuticals Incorporated stock a safe investment in uncertain markets2025 Top Decliners & Free Risk Controlled Daily Trade Plans - newser.com
Can machine learning forecast Vertex Pharmaceuticals Incorporated recoveryJuly 2025 Institutional & Free Weekly Chart Analysis and Trade Guides - newser.com
Vertex Pharmaceuticals price target raised to $414 from $408 at Barclays - TipRanks
Bank of New York Mellon Corp Lowers Holdings in Vertex Pharmaceuticals Incorporated $VRTX - MarketBeat
Bank of Montreal Can Sells 50,652 Shares of Vertex Pharmaceuticals Incorporated $VRTX - MarketBeat
Vertex Pharmaceuticals Inc (VRTX) 財務データ
収益
当期純利益
現金流量
EPS
0.16%
大文字化:
|
ボリューム (24 時間):